Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery

      Prostate cancer patients diagnosed with high Gleason score (≥8) and large tumors (≥T2c) are considered high-risk patients and >50% will develop an early biochemical relapse following radical surgery. Presently, there is no curative therapy available for patients with biochemical relapse. Based on encouraging clinical results from 6 relapsed prostate cancer patients treated under hospital exemption with Dendritic Cell (DC) vaccines we started an adjuvant, first in man, Phase I/II study using autologous, monocyte derived DCs targeting autologous tumor antigens from the primary tumor, hTERT and survivin. Twenty patients were included in the study. All patients had pathological stage pT2-pT3b and Gleason score 7b-10. Following surgery Prostate Specific Antigen (PSA) was <0,2 µg/L in all patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect